HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy

Oncology Today with Dr Neil Love · Jul 17, 2026 · 46m

Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:

Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)

Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)

Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)

Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)

Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung…